Edward Arrowsmith
Hematology | Oncology
605 Glenwood Dr Ste 200
Chattanooga, TN 37404
Chattanooga, TN 37404
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumors.
Journal: Investigational new drugs
Published: May 19, 2025
A Phase II Study to Evaluate the Efficacy of Commercially Available Molecularly Matched Targeted Therapies in the Second-Line Setting.
Journal: The oncologist
Published: January 27, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: August 19, 2024
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: September 22, 2023
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Journal: The oncologist
Published: July 27, 2023
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: November 29, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
Journal: JAMA oncology
Published: November 17, 2022
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
Journal: Journal for immunotherapy of cancer
Published: January 14, 2022
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Journal: Cancer
Published: July 06, 2021
Time to Rethink the Role of Clinical Pathways in the Era of Precision Medicine: A Lung Cancer Case Study.
Journal: JCO oncology practice
Published: April 19, 2021
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Journal: American journal of hematology
Published: September 15, 2020
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 13, 2020
Last Updated: 09/26/2026